Ludwig Cancer Research

What's New

First patient dosed in Phase I/IIa trial of lung cancer immunotherapy vaccine

Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600*, in patients with the most common type of...

You must enable all cookies to see Ludwig's twitter feed.

Success Stories

Ludwig Cancer Research celebrates 50 years of trailblazing cancer research

Disruptor of metastasis

Modeler of malignancy

See All Stories

News Releases

The point of no return: chromatin enforces cell fate decisions

November 29, 2021

Ludwig Lausanne team devises a method to selectively grow tumor-targeting T cells for cancer therapy

November 15, 2021

Ludwig Cancer Research study identifies cellular interactions essential to the immune attack on ovarian tumors

November 5, 2021

See All News

Publications

Ludwing Link Newsletter

Our newsletter keeps you up to date with the latest findings, developments and ideas from our global community of researchers.

Launch e-book

Download PDF

Annual Research Highlights Report

Our yearly collection of stories illustrating the depth and breadth of Ludwig’s life-changing science and the human side of research.

Launch e-book

Download PDF

Ludwig Cancer Research 2021 Annual Research Highlights

See All Publications

Ludwig In The News

See All Articles

Media Inquiries

For media inquiries, contact Rachel Reinhardt, vice president for communications, at +1 212 450 1582.

Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.